Here we compare the effects of vilazodone, a high efficacy serotonin reuptake inhibitor with potent 5-HT1A partial agonist properties, to fluoxetine, the prototype selective serotonin reuptake inhibitor (SSRI) approved for the treatment of depression, in the novelty suppressed feeding (NSF) paradigm. Here, HTR1A is linked to depressive disorder.